Octreotide and Insulin Detemir Interaction

Drug interaction information between Octreotide and Insulin Detemir.

Octreotide and Insulin Detemir have a documented moderate interaction in FDA labeling.

FDA drug labeling documents a moderate-severity interaction between Octreotide and Insulin Detemir. This page displays the available source-record category and label text. The category is not an individual risk estimate or medication-combination direction.

Drug A

Octreotide

Somatostatin Analog

Drug B

Insulin Detemir

Long-Acting Insulin

How They Interact

Octreotide can lower blood sugar, which adds to the effect of insulin and makes low blood sugar more likely.

Frequently Asked Questions

What SPL severity band is on file for Octreotide + Insulin Detemir?

Compiled FDA labeling labels this pair moderate. That is a source-record field, not an individual medication-combination decision.

Which drug in this pair has the larger labeled-interaction portfolio?

Octreotide has 14 labeled pairs on file vs Insulin Detemir's 11. In the moderate band specifically: Octreotide has 9 (also Insulin Aspart, Insulin Degludec, Insulin Glargine, Insulin Glulisine); Insulin Detemir has 3 (also Fluoxetine, Pramlintide).

What mechanism field is on file for Octreotide and Insulin Detemir?

Octreotide can lower blood sugar, which adds to the effect of insulin and makes low blood sugar more likely.

Octreotide's labeled portfolio outnumbers Insulin Detemir

SPL source-record counts only. This page's band is moderate · classes on file: Octreotide (Somatostatin Analog); Insulin Detemir (Long-Acting Insulin).

Octreotide

0 major · 9 moderate · 5 minor · 14 total

Insulin Detemir

0 major · 3 moderate · 8 minor · 11 total

Sources: FDA Drug Labels (SPL) via openFDA (2026). This is for informational purposes only and is not medical advice. This registry does not provide individual medication-combination directions.